06:58 AM EDT, 10/29/2026 (MT Newswires) -- Helsinn Healthcare secured approval from the UK Medicines and Healthcare products Regulatory Agency for the oral suspension of Akynzeo. The Switzerland-based pharmaceutical company said Thursday that the drug prevents acute and delayed nausea and vomiting tied to highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in adults.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.